Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.

Wiznia, Andrew; Church, Joseph; Emmanuel, Patricia; Eppes, Stephen; Rowell, Lucy; Evans, Claire; Bertasso, Anne

Wiznia, Andrew; Church, Joseph; Emmanuel, Patricia; Eppes, Stephen; Rowell, Lucy; Evans, Claire; Bertasso, Anne.

Affiliation

Wiznia A; Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. wiznia@worldnet.att.net

Pediatr Infect Dis J ; 26(9): 799-805, 2007 Sep.

Article in En | MEDLINE | ID: mdl-17721374

Subject(s)

HIV Envelope Protein gp41/administration & dosage; HIV Envelope Protein gp41/adverse effects; HIV Fusion Inhibitors/administration & dosage; HIV Fusion Inhibitors/adverse effects; HIV Infections/drug therapy; Peptide Fragments/administration & dosage; Peptide Fragments/adverse effects; Adolescent; Anti-Retroviral Agents/administration & dosage; Anti-Retroviral Agents/adverse effects; Anti-Retroviral Agents/pharmacokinetics; Child; Child, Preschool; Enfuvirtide; Female; HIV Antibodies/blood; HIV Envelope Protein gp41/pharmacokinetics; HIV Fusion Inhibitors/pharmacokinetics; HIV Infections/immunology; Humans; Male; Multicenter Studies as Topic; Peptide Fragments/pharmacokinetics; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / HIV Envelope Protein gp41 / HIV Infections / HIV Fusion Inhibitors Type of study: Clinical_trials / Guideline Limits: Adolescent / Child / Child, preschool / Female / Humans / Male Language: En Journal: Pediatr Infect Dis J Journal subject: DOENCAS TRANSMISSIVEIS / PEDIATRIA Year: 2007 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links